At Innogene Kalbiotech we enrich diagnostics, therapeutics and health care products by bringing in the latest breakthroughs in biology and biotechnology. Our products carry our mission that transforms patients’ health and lives that we believe will work towards bettering life globally.
We welcome collaborations in clinical research and have several ongoing clinical trials.
Our biosimilar monoclonal antibody, Rituximab, is currently in phase III trial under a collaboration with the licenser who is undertaking the trial in South America.
Innogene Kalbiotech has maintained oversight of Indonesia and The Philippines since 2013 for the Diffused Large B-cell Lymphoma indication. We also conducted a phase II trial of the humanized monoclonal antibody for the treatment of cervical cancer in Indonesia. The results of these trials will be published by the end of 2014.
There are two ongoing trials for our humanized monoclonal antibody for the treatment of head and neck cancer. The phase II trial in non-operable head and neck cancer is being conducted in Thailand and Singapore. The phase III trial in operable head and neck cancer is underway in Australia, South Korea, India, Saudi Arabia, South Africa, Singapore, Malaysia, Philippines, Thailand and Indonesia. We plan to open additional sites for this trial in China and Taiwan by 2015.
Innogene Kalbiotech and our sister companies also provide laboratory services such as BA (Bioavailabity) and BE (Bioequivalence) studies, QA (Quality Assurance) and other diagnostic services.